Video
Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discusses DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.
Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discussed DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.
She spoke about the benefits of DMT, what the treatment targets are, and early research of the drug.